// App-Quantinova.ai

: Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Researchers

Presenter

  • Meral Beksac

Principal Investigators

  • Tulin Tuglular

  • Francesca Gay

  • Roberto Mina

  • Eirini Katodritou

  • Ali Unal

  • Michele Cavo

  • Guner Hayri Ozsan

  • Vincent H.J. van der Velden

  • Berna Beverloo

  • Michael Vermeulen

  • Mark van Duin

  • Guldane Cengiz

  • Omur Gokmen Sevindik

  • Serena Merante

  • Kyriaki Manousou

  • Pieter Sonneveld

  • Evangelos Terpos

Medical Centers

  • Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Dokuz Eylul University, Izmir, Turkey

  • Department of Haematology, Theagenion Anticancer General Hospital, Thessaloniki, Greece

  • Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey, Ankara, Turkey

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, ATHENS, Greece

  • Department of Hematology, Ankara University Faculty Of Medicine Cebeci Hospital, Ankara, Turkey

  • Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands

  • Marmara University, Istanbul, Turkey

  • Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy

  • European Myeloma Network, Pavia, Italy

  • Department of Hematology, Faculty of Medicine, Erciyes University, Melikgazi, Kayseri, Turkey

  • DEPARTMENT OF CLINICAL GENETICS, ERASMUS MC, Rotterdam, Netherlands

  • Department of Hematology, Erasmus MC, Rotterdam, Netherlands

  • University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy

  • Health Data Specialists, Dublin, Ireland

Locations

  • Turkey

  • Italy

  • Netherlands

  • Greece

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Circulating tumor cells

  • Cluster of Differentiation 19

  • Cluster of differentiation 45

  • Cluster of Differentiation 38

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

  • Cluster of Differentiation 56

  • Syndecan-1

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • daratumumab Intravenous

  • Bortezomib

Outcome

  • N/A

Study Design

  • Efficacy

  • Fixed Dose

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved